GLP-1 receptor agonists, such as semaglutide and tirzepatide, are widely used for metabolic control. Yet their influence on circadian timing is less discussed. Emerging data suggest these agents can shift sleep-wake cycles, possibly through central GLP-1 receptors in the suprachiasmatic nucleus. When circadian rhythms are displaced, sleep architecture suffers. Slow-wave sleep (SWS) may shorten, REM latency may alter, and awakenings increase. This is where Selank (a synthetic anxiolytic heptapeptide) enters the picture. Russian researchers have long studied Selank for its capacity to normalize stress-induced sleep fragmentation. But its effects during pharmacologically induced circadian shifts remain underexplored.
Professor V. Kh. Khavinson and his colleagues at the St. Petersburg Institute of Bioregulation and Gerontology have published extensively on peptide regulation of biorhythms. Their work with Epitalon (a tetrapeptide) demonstrated pineal-mediated circadian correction (Khavinson 2003). Selank, developed at the Institute of Molecular Genetics, shares conceptual roots with this school. It is a modified fragment of tuftsin, designed to resist enzymatic degradation while retaining anxiolytic properties. The peptide's mechanism involves modulation of GABAergic transmission and possibly enkephalinase inhibition, which prolongs endogenous opioid activity (Zozulya 2008). This dual action on anxiety and endogenous opioid tone may explain its sleep effects.
When GLP-1 agonists shift the circadian phase, the sleep period may no longer align with the endogenous melatonin onset. This misalignment can produce a state of hyperarousal at bedtime. Selank's primary clinical indication is anxiety, and its sleep benefits are often considered secondary. However, studies in patients with neurasthenia showed that Selank increased total sleep time and reduced nocturnal awakenings without causing daytime sedation (Andreeva 2012). The peptide appears to normalize the sleep EEG pattern, increasing delta power during the first sleep cycle. This is relevant because GLP-1-induced circadian shifts often blunt the delta power surge that normally occurs in early sleep.
One might assume that any anxiolytic would improve sleep. Except, and this matters, Selank does not behave like benzodiazepines. Benzodiazepines suppress SWS and alter sleep spindles. Selank, in animal models, preserved SWS and even enhanced it under stress conditions (Seredenin 2009). The difference may lie in Selank's lack of direct GABA-A receptor agonism. Instead, it appears to modulate the expression of GABAergic genes, possibly through a genomic mechanism that takes hours to develop. This delayed effect could be advantageous when circadian rhythms are shifting, because it allows the sleep homeostat to adjust gradually rather than forcing a pharmacological sleep state.
Our earlier discussion of Selank vs DSIP for circadian rhythm repair after jet lag highlighted DSIP's direct promotion of SWS. DSIP (delta sleep-inducing peptide) is a nonapeptide that increases SWS when administered centrally. But DSIP's effects are inconsistent when given peripherally, and its half-life is very short. Selank, by contrast, is stable in plasma and crosses the blood-brain barrier. Its anxiolytic action may indirectly support sleep by reducing the cognitive arousal that interferes with sleep onset. In the context of GLP-1-induced circadian shifts, where the sleep drive is misaligned, reducing anxiety at bedtime could be more practical than directly inducing SWS.
GLP-1 agonists are known to affect the hypothalamic-pituitary-adrenal (HPA) axis. Some studies report elevated cortisol after chronic administration, which could contribute to sleep disruption. Selank has been shown to normalize cortisol levels in patients with anxiety disorders (Kozlovskaya 2010). This normalization may be due to its effects on the expression of corticotropin-releasing hormone (CRH) in the amygdala. By dampening the stress response, Selank could mitigate the HPA-mediated sleep fragmentation that accompanies circadian misalignment. This mechanism is distinct from that of DSIP, which acts more directly on sleep-regulating nuclei.
Another peptide worth mentioning is Tesamorelin (a growth hormone-releasing hormone analog). Tesamorelin increases slow-wave sleep via GH secretion, as we explored in Tesamorelin vs DSIP: GH-mediated slow-wave sleep enhancement. But Tesamorelin's effects depend on intact somatotropic axis function, which may be altered by metabolic disease. Selank's anxiolytic mechanism is independent of GH, making it a candidate for individuals with GLP-1-induced circadian shifts who may have metabolic dysregulation. The combination of Selank with a GLP-1 agonist has not been formally studied, but theoretical synergy exists: the GLP-1 agonist improves metabolic parameters, while Selank stabilizes the emotional and sleep responses to the circadian shift.
Animal studies provide some insight into Selank's effects on circadian gene expression. In rats subjected to chronic stress, Selank normalized the expression of Per2 and Bmal1 in the hippocampus (Gudasheva 2015). These clock genes are also expressed in peripheral tissues and are sensitive to metabolic signals. GLP-1 agonists can alter clock gene expression in the liver and adipose tissue. If Selank can stabilize clock gene rhythms in the brain, it might help realign the central and peripheral clocks during GLP-1 therapy. This hypothesis remains untested, but it aligns with the peptide bioregulator concept advanced by Khavinson's group.
One must consider the timing of Selank administration. If given in the morning, its anxiolytic effect may reduce daytime anxiety without causing sedation. If given in the evening, it could facilitate sleep onset. However, its long-term effects on sleep architecture are not well characterized. Most human studies have been short-term, lasting two to four weeks. The peptide's safety profile appears favorable, with no reports of dependence or withdrawal. But the interaction with GLP-1 agonists is unknown. Both agents can affect glucose metabolism, and Selank has been reported to potentiate insulin secretion in some models (Kozlovskaya 2010). This could be beneficial or problematic, depending on the individual's metabolic state.
In the broader context of circadian resynchronization, Selank may be compared to other peptides like Epitalon. Epitalon has been shown to restore age-related declines in melatonin secretion and improve sleep quality in elderly patients (Khavinson 2003). But Epitalon's effects are primarily on the pineal gland, while Selank's are on the limbic system. For GLP-1-induced circadian shifts, where the pineal melatonin rhythm may be intact but the sleep-wake cycle is displaced, Selank's anxiolytic action might be more directly relevant. We discussed a related stack in Tesamorelin and Epitalon stack for circadian alignment, which targets both GH and pineal function. Adding Selank to such a stack could address the psychological component of circadian misalignment.
Clinical data on Selank for sleep are limited but suggestive. In a study of 60 patients with generalized anxiety disorder, Selank improved subjective sleep quality scores on the Pittsburgh Sleep Quality Index (PSQI) after two weeks of treatment (Andreeva 2012). Polysomnography in a subset showed increased SWS percentage and decreased REM latency. These changes are opposite to those seen with SSRIs, which often suppress REM sleep. The preservation of REM sleep is important because REM sleep is involved in emotional memory processing. During circadian shifts, REM sleep may be particularly vulnerable to disruption. Selank's ability to maintain REM sleep while reducing anxiety could support emotional adaptation to the new schedule.
There is also the question of whether Selank can prevent the development of sleep disorders during GLP-1 therapy. If started concurrently with a GLP-1 agonist, Selank might attenuate the initial sleep disruption that some patients experience. This prophylactic use has not been studied, but it is plausible given Selank's mechanism of normalizing stress responses. The peptide's effects on the immune system, including modulation of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), may also play a role. These cytokines are involved in sleep regulation and are elevated in metabolic disorders. GLP-1 agonists reduce inflammation, and Selank could complement this effect.
Despite these promising findings, many open questions remain. The optimal dose and timing of Selank for sleep during circadian shifts are unknown. Most studies used intranasal administration, which provides rapid brain delivery. But the bioavailability and pharmacokinetics in the context of GLP-1 therapy have not been characterized. Long-term effects on sleep architecture and circadian gene expression need investigation. The potential for interactions with other peptides, such as DSIP or Epitalon, is unexplored. And the influence of individual differences in clock gene polymorphisms on Selank's efficacy is a topic for future research.
Western sleep medicine has largely ignored Selank, focusing instead on melatonin agonists and orexin antagonists. But the Russian peptide literature offers a different perspective: that sleep is not just a brain state but a whole-organism phenomenon regulated by bioregulators. Selank, as an anxiolytic peptide, may occupy a unique niche in the management of sleep disruption caused by metabolic therapies that shift circadian rhythms. Its safety profile and non-sedating nature make it an attractive candidate for further study. However, until controlled trials are conducted, its use remains experimental.
Long-term safety data for many peptides discussed here is limited. Risk profiles should be interpreted accordingly.